Archuleta T D, Devetten M P, Armitage J O
Section of Hematology/Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Panminerva Med. 2004 Mar;46(1):61-74.
Hematopoietic stem cell transplantation has become increasingly important in the treatment of hematologic malignancies over the past 20 years. While it is associated with significant morbidity, it offers the only chance of cure in many circumstances. Autologous and allogeneic transplantation have been used successfully to treat a variety of hematologic malignancies. These 2 approaches offer different risks and benefits which are discussed in this review. Timing of transplantation and selection of patients are also discussed. New innovations in stem cell transplantation including umbilical cord blood and non-myeloablative transplantation are reviewed.
在过去20年中,造血干细胞移植在血液系统恶性肿瘤的治疗中变得越来越重要。虽然它伴随着显著的发病率,但在许多情况下它提供了唯一的治愈机会。自体和异体移植已成功用于治疗多种血液系统恶性肿瘤。这两种方法具有不同的风险和益处,本文将对此进行讨论。还将讨论移植时机和患者选择。本文将对干细胞移植的新进展进行综述,包括脐带血和非清髓性移植。